Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Silence Therapeutics ( (SLN) ) just unveiled an announcement.
On December 18, 2025, Silence Therapeutics plc appointed its Executive Vice President and Chief Financial Officer, Rhonda Hellums, to the company’s Board of Directors as an executive director, with her initial term running until the end of the 2026 Annual General Meeting of Shareholders. Hellums will serve on the board without additional compensation and will not sit on any board committees, and the company emphasized that her appointment did not arise from any special arrangements, family relationships, or related-party transactions, underlining standard governance practices for stakeholders monitoring board independence and oversight.
The most recent analyst rating on (SLN) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.
Spark’s Take on SLN Stock
According to Spark, TipRanks’ AI Analyst, SLN is a Neutral.
The overall score is driven by technical analysis and corporate events, which show positive momentum and strategic progress. However, financial performance and valuation are significant concerns due to profitability challenges and negative equity.
To see Spark’s full report on SLN stock, click here.
More about Silence Therapeutics
Silence Therapeutics plc operates in the biopharmaceutical sector, focusing on developing therapeutics using its proprietary RNA interference (RNAi) technology platform to address a range of serious diseases.
Average Trading Volume: 215,108
Technical Sentiment Signal: Sell
Current Market Cap: $300.9M
See more insights into SLN stock on TipRanks’ Stock Analysis page.